{"entity":{"id":"folr1","kind":"target","name":"Folate receptor alpha","aka":[],"tldr":"Folate receptor alpha is a vitamin receptor that ovarian cancer cells carry in large numbers, used as the docking site for the ADC mirvetuximab.","summary":"FRα is overexpressed in high-grade serous ovarian cancer, endometrial cancer, and lung adenocarcinoma. Mirvetuximab soravtansine (Elahere) is approved in FRα-high platinum-resistant ovarian cancer (MIRASOL). Next-generation FRα ADCs with topoisomerase-I payloads (ZW191, luveltamab tazevibulin, rinatabart sesutecan) target lower-expressing tumours.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Folate_receptor_1","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Folate_receptor_1"}],"tags":["adc-target"],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"FOLR1","hgnc":"HGNC:3791","ensembl":"ENSG00000110195","uniprot":"P15328","entrez":"2348","biology":"GPI-anchored folate transporter; limited to apical surfaces in normal kidney, lung, and choroid plexus.","whereFound":["High-grade serous ovarian (~80% any expression)","Endometrial","NSCLC adenocarcinoma","TNBC (subset)"],"targetClass":"surface-antigen","prevalence":[]},"route":"/targets/folr1/","neighbours":{}}